This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Haemonetics (HAE) Stock Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) better-than-expected results and strong Plasma sales.
Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail
by Zacks Equity Research
Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.
McKesson (MCK) Up 7.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nevro's (NVRO) PDN Therapy Gets Positive Coverage Updates
by Zacks Equity Research
Latest favorable coverage decisions for Nevro's (NVRO) PDN Therapy are expected to serve a wider patient pool.
3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Here's Why You Should Hold on to Chemed (CHE) Stock Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) better-than-expected earnings and impressive Roto-Rooter results.
Medtronic (MDT) Obtains U.S. Distribution Rights for BioButton
by Zacks Equity Research
Medtronic's (MDT) new deal with BioIntelliSense will ensure accessibility to BioButton for continuous vital sign measurements of general care patients in the United States.
Boston Scientific (BSX) Grows Operationally Amid Macro Issues
by Zacks Equity Research
In the Asia Pacific region, Boston Scientific (BSX) grows operationally with notable performance in Japan, India and the ASEAN countries.
Patterson Companies (PDCO) Q1 Earnings & Sales Miss Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter 2023 results were adversely impacted by unfavorable currency movements.
Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.
Veeva Systems (VEEV) Beats on Q2 Earnings, Revises FY23 View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both of its segments.
Zacks.com featured highlights include TotalEnergies, J.B. Hunt Transport Services, Archer-Daniels-Midland , McKesson and Republic Services
by Zacks Equity Research
TotalEnergies, J.B. Hunt Transport Services, Archer-Daniels-Midland , McKesson and Republic Services are part of Zacks Screen of the Week article.
Henry Schein (HSIC) Inks Deal to Acquire Midway Dental Supply
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Midway Dental Supply complements its efforts to offer products and services that deliver more effective, high-quality patient care.
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.
5 Dividend Growth Stocks to Beat September Slump
by Sweta Killa
Dividend growth stocks like TotalEnergies, J.B. Hunt, Archer-Daniels-Midland, McKesson and Republic Services seem like solid choices for September.
Bruker (BRKR) Debuts Innovations for Proteomics & Metabolomics
by Zacks Equity Research
Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.
Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business
by Zacks Equity Research
According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.
Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?
by Zacks Equity Research
Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward.
Here's Why You Should Hold on to Nevro (NVRO) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.
Teladoc Health (TDOC) Ties Up to Upgrade RPM Care in Canada
by Zacks Equity Research
Teladoc Health (TDOC) teams up with Cloud DX to bring its virtual care capabilities to the latter's platform and dispense advanced RPM solutions to the Canadian residents.
Myriad Genetics (MYGN) Gets Extensive Coverage for BRACAnalysis
by Zacks Equity Research
Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
What's in Store for Patterson Companies (PDCO) in Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at the Animal Health segment.
Catalent (CTLT) Q4 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its fourth-quarter fiscal 2022 top line.